Navigation Links
ANP to present at and attend major US investment, partnering and industry conferences
Date:8/28/2013

USA Investor/Media: Joshua Drumm 212-375-2664; jdrumm@tiberend.com

Australia Investor/Media: Simon Watkin +61 413 153272; simon@marketconnect.com.au

Antisense Therapeutics Limited (ASX: ANP) is an Australian publicly listed biopharmaceutical drug discovery and development company. Its mission is to create, develop and commercialise second generation antisense pharmaceuticals for large unmet markets. ANP has 4 products in its development pipeline that it has in-licensed from Isis Pharmaceuticals Inc., world leaders in antisense drug development and commercialisation - ATL1102 (injection) which has successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with multiple sclerosis, ATL1103 a second-generation antisense drug designed to block GHr production and thereby lower blood IGF-I levels and is in clinical development as a potential treatment for growth and other GH-IGF-I disorders, ATL1102 (inhaled) which is at the pre-clinical research stage as a potential treatment for asthma and ATL1101 a second-generation antisense drug at the pre-clinical stage being investigated as a potential treatment for cancer.


'/>"/>
SOURCE Antisense Therapeutics Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Cambridge Semantics to Present on ‘Smart Data’ During Deep-Dive Workshop at 2013 Big Data Innovation Summit
2. EnduRx Pharmaceuticals to Present at 2013 Rocky Mountain Life Science Investor and Partnering Conference
3. Convoy Therapeutics to Present at 2013 Rocky Mountain Life Science Investor and Partnering Conference
4. AbbVie to Present at Morgan Stanley Global Healthcare Conference
5. Cambridge Semantics to Present on Smart Data and Competitive Intelligence Informatics at 2013 Pharma CI Conference & Exposition
6. iLab Solutions to Present SRA International Webinar for Research Administrators
7. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE MIDWEST IDEAS INVESTOR CONFERENCE
8. Bayer CropScience Presents on Bee Health and Stewardship at International Pollinator Conference
9. GW Pharmaceuticals to Present at the 33rd Annual Canaccord Genuity Growth Conference
10. Sangamo BioSciences Announces Presentation At The 2013 Wedbush Life Sciences Management Access Conference
11. Novus International to Present Scientific Findings on Prebiotics during Aquaculture Europe 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... 2016 , ... Researchers at the Universita Politecnica delle Marche in Ancona combed ... pleural mesothelioma. Their findings are the subject of a new article on the Surviving ... signposts in the blood, lung fluid or tissue of mesothelioma patients that can help ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
(Date:6/23/2016)... HOUSTON , June 23, 2016 ... agreement with the Cy-Fair Sports Association to serve ... of the agreement, Houston Methodist Willowbrook will provide ... education and connectivity with association coaches, volunteers, athletes ... partner with the Cy-Fair Sports Association and to ...
(Date:6/23/2016)...  The Biodesign Challenge (BDC), a university competition that ... living systems and biotechnology, announced its winning teams at ... New York City . The teams, ... at MoMA,s Celeste Bartos Theater during the daylong summit. ... curator of architecture and design, and Suzanne Lee ...
Breaking Biology Technology:
(Date:4/26/2016)... 27, 2016 Research and ... Biometrics Market 2016-2020"  report to their offering.  , ... The analysts forecast the global multimodal biometrics ... during the period 2016-2020.  Multimodal biometrics ... such as the healthcare, BFSI, transportation, automotive, and ...
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
(Date:3/29/2016)... 29, 2016 LegacyXChange, Inc. (OTC: ... and SelectaDNA/CSI Protect are pleased to announce our successful ... a variety of writing instruments, ensuring athletes signatures against ... collectibles from athletes on LegacyXChange will be assured of ... DNA. Bill Bollander , CEO states, ...
Breaking Biology News(10 mins):